Clinical Trial: FDA Stays Silent on Trovan Charges

October 1, 2001
Kevin Gopal
Kevin Gopal

Kevin Gopal is Pharmaceutical Executive's international correspondent, covering pharma and regulatory issues around the word. He is also a political columnist for North West Business Insider, one of the UK's leading regional business magazines. He started his career as a journalist at SiYu, the UK's Chinese community magazine, before joining the PE staff.

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-10-01-2001, Volume 0, Issue 0

Lagos, Nigeria-FDA refused to confirm or deny that it was launching a criminal investigation into Pfizer’s conduct during a 1996 clinical trial for Trovan (alatrofloxacin) in Nigerian patients.

Related Content:

News